Connect with us

Media & Technology

Wisconsin CBD Grow; the Rise of Integrated Cannabis Solutions, Inc. (OTCMKTS: IGPK)

Published

on

Integrated Cannabis Solutions, Inc. (OTCMKTS: IGPK) is making a powerful move up the charts in recent trading quickly attracting legions of new shareholders and emerging as a volume leader in small caps. On Friday alone IGPK traded 484 million shares or $25 million in dollar volume after the Company stated it is close to publishing its current audited fins. IGPK has been working hard behind the scenes taking proactive steps to increase shareholder value and is now virtually debt free with just $500k in total liabilities and no convertible debt. Integrated has entered into contract to purchase a 200-acre farm with 160 acres of tillable land on which to grow and process hemp, after its filed S1 Registration is effective. The Company is also negotiating to purchase a 9.5 acre facility build out in Lancaster, CA encompassing 200,000 square feet total facilities for grow and production operations.

Marijuana and CBD stocks are on the rise in recent months as New Jersey, Arizona, Montana and South Dakota legalize cannabis for recreational use. Also the house just passed sweeping legislation that would decriminalize marijuana and expunge nonviolent marijuana-related convictions although the bill is unlikely to pass. CBD is booming and is projected to reach $4.7 billion in US sales in 2020 up from $4.1 billion in 2019. According to a new reported from reserchandmarkets.com; The U.S. cannabidiol market is estimated to reach US$13.39 billion in 2024, growing at a CAGR of 42.36% for the period spanning 2020-2024.

Integrated Cannabis Solutions, Inc. (OTCMKTS: IGPK) is a publicly traded company under the ticker “IGPK” the Company is seizing on the momentum of the new Hemp bill in Wisconsin once known as “The Hemp Capital” of the United States. The Company has an opportunity to establish a strong foothold in the State of Wisconsin and become a significant player in the CBD market. Integrated’s CEO has experience in the CBD sector, having just successfully completed a test grow on 15 acres of land in Colorado. Integrated plans to piggyback off that experience and duplicate its success in Wisconsin. The Company has been negotiating to acquire controlling interest in an active Cannabis Dispensary in California and has plans to purchase a 9.5 acre facility build out in Lancaster, CA encompassing 200,000 square feet total facilities for grow and production operations.

A subsidiary Limited Liability company Integrated Farming Solutions, LLC was setup to hold all the farming operations of the Company. Integrated has entered into contract to purchase a 200-acre farm with 160 acres of tillable land on which to grow and process hemp, after its filed S1 Registration is effective. The cost of the farm is $1,595,000 and includes 4 vehicles and 4 bungalows that have been rented out over the years creating a destination getaway location. The farm has a long history dating back to early 1900’s of successful harvests of hemp and later tobacco the farm is still producing successful harvests of corn. Wisconsin’s soil is rich due to the fact the land only freezes about 4 feet deep which allows water to flow underneath, nourishing the soil. The Company plans to develop a Co-op with surrounding farms and teach them how to grow hemp. Then Integrated will purchase biomass from those farmers and give them a small percentage of the finished product after it has been processed. Integrated has been APPROVED for a Grow and Processing license in Wisconsin. For more on the Company’s operations go here: igpk.org/operations/

To Find out the inside Scoop on IGPK Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

IGPK

Integrated Cannabis filed its S1 Registration on February 12, 2020 which can be found here. The S-1 is key to IGPK’s long-term success. With the S-1 in place IGPK can seek financial commitments to purchase the farm and purchase another 50% of the dispensary in Los Angeles. The S-1 tells institutional level investors the Company is committed to transparency. The Company has held discussions with investment firms who finance cannabis operations. These investment firms only invest in SEC reporting companies. Raising money in the OTC is hard enough. IGPK recognizes it needs to give prospective investors many reasons to invest, including moving from OTC Pink to a higher exchange.

While the Company has not been putting out much press management has been working hard behind the scenes taking proactive steps to increase shareholder value. The actions concerning payroll, stock options, and convertible debt have reduced reported outstanding debt on IGPK’s books significantly resulting in IGPK becoming virtually debt free with just $500k in total liabilities and no convertible debt. IGPK’s priorities now that they have filed the S-1 are closing the pending deals in California, getting up-listed to the OTCQB and start producing revenues.  On December 4 IGPK posted on twitter: “IGPK is close to publishing its current audited fins. To answer a few questions: The O/S will not be raised any further, the Pref shares are owned by our CEO and do not have to be converted, the fins will have audited 2019 and audit reviewed 9 months 2020, OTCQB is the target.”

For More on IGPK Subscribe Right Now!

Currently making a powerful move up the charts IGPK is an exciting story developing in small caps; the has entered into contract to purchase a 200-acre farm with 160 acres of tillable land on which to grow and process hemp, after its filed S1 Registration is effective. The Company is also negotiating to purchase a 9.5-acre facility build out in Lancaster, CA encompassing 200,000 square feet total facilities for grow and production operations. The stock is getting noticed fast trading 484 million shares or $25 million in dollar volume on Friday alone after the Company stated it is close to publishing its current audited financial statements. IGPK has been working hard behind the scenes taking proactive steps to increase shareholder value and is now virtually debt free with just $500k in total liabilities and no convertible debt. IGPK is focused on closing the pending deals in California, getting up-listed to the OTCQB and starting to produce revenues. We will be updating on IGPK when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with IGPK.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in IGPK either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.